All News
Filter News
Found 79 articles
-
Recce Pharmaceuticals Announces Resignation of Director & Chief Research Officer Dr. Graham Melrose
7/6/2020
Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melrose’s executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board. Dr. Melrose said: “Recce was formed with a mission to address the global health threat of antibiotic resistance and I feel we have made generationally s
-
Recce Pharmaceuticals Announces First-Quarter 2020 Financial Results and Provides Operational Highlights
4/30/2020
Recce Pharmaceuticals Ltd, the company developing a new class of broad-spectrum synthetic antibiotics, reported its March 2020 quarter results and operational highlights.
-
BioSpace Global Roundup, April 23
4/23/2020
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines. -
Recce Pharmaceuticals Announces More Positive Data on RECCE® 327 Against MRSA Superbug in Burn Wound Animal Model
4/23/2020
Highlights: Statistically significant reduction in MRSA superbug bacterial load and higher percentage of wound contraction with RECCE ® 327 as compared to Soframycin in rat model for topical burns Study reinforces the potential of RECCE ® 327 against drug-resistant superbugs
-
Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Influenza A Respiratory Virus Infection in Animal Model
4/20/2020
Highlights: Dramatic reduction in viral load in the lungs of mice treated with RECCE ® 327 as compared to the approved antiviral drug treated and vehicle control untreated groups RECCE ® 327’s unique mechanism of action reinforces efficacy against both bacterial cells and enveloped viruses SYDNEY, Australia, April 20, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ), the company developing a new class of broad-spectrum synthetic antibiotics, today announced posit
-
Clinical Catch-Up: April 6-10
4/13/2020
It was a very busy week for clinical trial news. Here’s a look. -
Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects
4/8/2020
Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE ® 327 in 40 healthy subjects as a single ascending dose Estimated start-to-completion with data read-outs less than 12 months from now First patients expected to be dosed in second half of 2020
-
Recce Pharmaceuticals Releases White Paper Providing Data and Market Positioning of its Synthetic Polymer Antibiotics
10/23/2019
Recce Pharmaceuticals Ltd published a white paper providing pre-clinical and experimental data on its new synthetic antibiotics and outlining the market need, its anticipated market positioning and development strategy.
-
Recce Completes Raising of AU$6.76 million
10/10/2019
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
-
AU$5m Federal Government Grant for University and Industry Collaboration with Recce Pharmaceuticals
8/30/2019
Recce Pharmaceuticals Ltd announced a successful grant application as one of five Industrial Partners in collaboration with 16 University and Public Health Organisations, to establish a National Anti-Microbial Resistant Research Hub in Sydney, Australia to combat antimicrobial resistance.
-
FDA Positive Response for Recce Scaled Manufacture and Quality
8/26/2019
Recce Pharmaceuticals Ltd announced advances in scaled manufacture and drug quality following positive Food and Drug Administration feedback to its Chemistry, Manufacturing, and Controls data pack.
-
Key Family 2 Patent Granted in Europe for RECCE® Antibiotics
8/8/2019
Recce Pharmaceuticals Limited announced the European Patent Office has granted its patent applications for wholly owned RECCE® antibiotics, including lead compound RECCE® 327 furthering marketing/manufacturing monopolies and expanding clinical indications.
-
Recce to Give Opening R&D Address at 2019 World Antibiotic Resistance Congress
8/1/2019
Dr John Prendergast will showcase the potential of New Synthetic Antibiotics
-
Recce Board Changes - Appointment of Independent Chair and Additional Director
7/9/2019
Recce Pharmaceuticals Ltd, the company developing a new class of synthetic antibiotics, announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer.
-
Recce Meets Antibiotic Leaders to Explore Commercial and Clinical Opportunities
10/26/2018
Reece will be represented at the World Anti-Microbial Resistance Congress in Washington D.C., 25 - 26 October 2018.
-
Update on Progress of Broad Spectrum Antibiotic RECCE®327 Towards Clinical Trials
7/17/2018
Recce Pharmaceuticals Ltd today provided an update on its progress towards the start of human trials of its lead compound RECCE®327, for the treatment of sepsis, including a simple clinical trial design.
-
Recce Pharmaceuticals Ltd Data Submission & Further Communication Request With Us FDA
2/15/2018
Recce Pharma today announced it has submitted additional data to the FDA, including an additional communication request.
-
AusIndustry Awards Recce Support for AU$5.6m of Technically Advanced Overseas Drug Development
1/15/2018
The funds include and cover some expenditure already undertaken and apply to all antibiotics under development.
-
Recce Release: Pharma’s Lead Compound Reduces Illness In Mice Infected By Resistant E. Coli Bacteria
1/18/2017